4basebio and Genezen expand collaboration to advance synthetic DNA for viral vector manufacturing
The commercial partnership combines 4basebio’s cell-free hpDNA platform with Genezen’s viral vector CDMO capabilities to provide cell and gene therapy developers with an alternative to conventional plasmid DNA manufacturing.
4basebio and Genezen have expanded their non-exclusive collaboration to provide cell and gene therapy developers with access to 4basebio’s synthetic hpDNA technology through Genezen’s viral vector development and manufacturing services.
The partnership is intended to support programmes from early development through clinical and commercial manufacturing by combining cell-free DNA production with Genezen’s viral vector process and manufacturing infrastructure.
Field | Content |
Alert Type | Deal |
Companies | 4basebio; Genezen |
Deal Type | Strategic commercial collaboration |
Asset or Company | 4basebio’s hpDNA synthetic DNA platform integrated with Genezen’s viral vector development and manufacturing services |
Therapy Area(s) | Cell and gene therapy; Genetic medicines |
Technology or Modality | Synthetic cell-free DNA; AAV and other viral vector manufacturing |
Deal Value | Financial terms were not disclosed. |
Development Stage | Platform collaboration supporting programmes from research and early development through clinical and commercial manufacturing |
Geography | Global |
What Happened | On 26 August 2026, 4basebio and Genezen announced an expanded, non-exclusive commercial collaboration giving drug developers access to 4basebio’s Research Use Only, High-Quality and GMP-grade hpDNA through Genezen’s viral vector development and manufacturing services. Genezen will offer 4basebio’s synthetic DNA for viral vector applications, creating an integrated route from DNA starting material through vector manufacturing. The companies did not disclose financial terms or identify individual therapeutic programmes covered by the collaboration. (GlobeNewswire) |
Why It Matters | Plasmid DNA is widely used as a starting material in viral vector production, making its manufacturing timeline, purity, material requirements and scalability relevant to cell and gene therapy development. 4basebio’s enzymatic process produces DNA without bacterial backbone sequences or antibiotic resistance genes and offers Genezen customers an alternative starting material that could streamline vector manufacturing, although programme-level benefits will need to be demonstrated in individual applications. (GlobeNewswire) |
Supporting Context | In AAV production, 4basebio says its hpDNA template has demonstrated titres comparable with plasmid DNA while requiring approximately 30% less DNA mass and transfection reagent. The company also says its cell-free process can shorten DNA production timelines compared with conventional plasmid manufacturing; these performance claims come from 4basebio and should not be interpreted as guaranteed outcomes for every manufacturing programme. (GlobeNewswire) |
Strategic Rationale | 4basebio gains an additional commercial channel for its synthetic DNA technology through an established viral vector CDMO, while Genezen expands the manufacturing options it can offer cell and gene therapy developers. The partnership is designed to allow developers to incorporate synthetic DNA into manufacturing strategies from early development while retaining a route towards GMP and commercial-scale production. (GlobeNewswire) |
Potential Impact | Wider use of cell-free synthetic DNA could reduce dependence on traditional bacterial plasmid manufacturing in some viral vector programmes and potentially improve manufacturing efficiency and scalability. The extent of any benefit will depend on individual vector processes and successful adoption by Genezen customers. |
Key Takeaway | The expanded collaboration integrates 4basebio’s synthetic DNA technology with Genezen’s viral vector CDMO services, giving gene therapy developers another manufacturing route from early development through commercial scale. |
What to Watch | Adoption of hpDNA by Genezen customers, disclosure of specific programmes using the integrated platform and evidence showing whether the reported material and timeline efficiencies translate into clinical and commercial-scale viral vector manufacturing. |
Primary Source | 4basebio / Genezen collaboration announcement |
Relevant Date | 26 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentários